Andrew is co-founder and co-Chief Executive Officer at Cajal Neuroscience, a biotechnology company integrating disease-focused genetics and human data with state-of-the-art experimental capabilities to discover novel targets and therapeutics for neurodegeneration
Prior to Cajal, Andrew was Senior Director of Business Development at Celgene, where he led the execution of Celgene’s cell therapy and immuno-oncology partnerships and transactions. He also previously led a team in Translational Medicine at Celgene, focused on leveraging novel single cell sequencing techniques for target discovery in oncology.
Throughout his industry career, Andrew has continued to practice as a clinical geneticist at the University of Washington Medical Center and brings this unique perspective to the challenge of understanding neurodegeneration and cancer. Andrew received his MD and MBA degrees from Harvard Medical School and Harvard Business School, before completing his residency and fellowship at the University of Washington in internal medicine and medical genetics.